Please login to Zacks.com or register to post a comment.
They're hand-picked from the list of Zacks Rank #1 Strong Buys. Our experts predict that their prices will jump the soonest.
Today, you can see them free.
| No Recent Quote currently available |
|
My Portfolio Tracker One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today. |
Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.
Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.
Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.
My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.
| Company Name | Symbol | %Change |
|---|---|---|
| STAAR SURGIC | STAA | 10.98% |
| DTS INC | DTSI | 6.89% |
| ANIKA THERAP | ANIK | 6.04% |
| LUMOS NETWOR | LMOS | 5.70% |
| INSTEEL IND | IIIN | 5.28% |
Please login to Zacks.com or register to post a comment.
Resources
Client Support
Zacks Research is Reported On:
Zacks Investment Research
is an A+ Rated BBB
Accredited Business.
Copyright 2013 Zacks Investment Research
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1986 it has nearly tripled the S&P 500 with an average gain of +26% per year. These returns cover a period from 1986-2011 and were examined and attested by Baker Tilly, an independent accounting firm.
Visit performance for information about the performance numbers displayed above.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This page is temporarily not available. Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext. 9339.
Supervalu Inc. (SVU - Analyst Report) is slated to release its second quarter of fiscal 2013 results before the opening bell on October 18, 2012. The Zacks Consensus Estimate for the second quarter is pegged at 13 cents (year-over-year decline of 53.6%) on revenues of $8.04 billion (year-over-year decline of 4.6%).
First Quarter Recap
Supervalu, one of the largest grocery chains in the U.S., reported first quarter fiscal 2013 earnings per share of 19 cents, missing the Zacks Consensus Estimate by 50% and the prior-year quarter earnings by 45.7%. The lower-than-expected results were due to sluggish sales in the quarter.
Supervalu’s total sales dipped 4.5% to $10.6 billion in the first quarter of fiscal 2013 from prior-year sales of $11.1 billion. Revenue also missed the Zacks Consensus Estimate of $10.9 billion. Lower customer spending due to the ongoing economic challenges, aggressive pricing by competitors and decline in same store sales negatively impacted the company’s sales.
Agreement of Estimate Revisions
Over the past 30 days, only 1 of the 12 analysts covering the stock revised their earnings estimate for the second quarter of fiscal 2013. The revision was in the downward direction. None of the analysts revised their estimates in the opposite direction.
Likewise, for fiscal 2013, only 1 of the 13 analysts changed their estimate in the negative direction over the past 30 days. None of the analysts have revised it in the opposite direction.
The downward revision in estimates can be attributed to the burden of rising input costs along with consistently declining same store sales.
Magnitude of Estimate Revisions
The Zacks Consensus Estimates for the second quarter and fiscal year 2013 have remained static over the past 30 days at 13 cents and 66 cents per share, respectively.
Surprise History
Supervalu has surpassed earnings estimates in two of the last four quarters. It has met the earnings estimate in one quarter, while missing it in another quarter. The earnings surprise ranges from a negative 50.0% to a positive 40%, with the average earnings surprise being negative 0.48%.
Our Recommendation
We feel that Supervalu and its peers are facing tough times due to low disposable income of consumers. Moreover, the U.S. Food and Drug Administration (FDA) is increasingly becoming more and more vigilant regarding food and health standards. Adverse publicity regarding food and drugs is affecting consumer confidence and preventing them from buying the company’s products resulting in product and delivery disruptions.
Supervalu faces stiff competition from Wal-Mart Stores Inc. (WMT - Analyst Report), The Kroger Co. (KR - Analyst Report) and Safeway Inc. (SWY - Analyst Report). Currently, we have a Neutral recommendation on the stock. Further, Supervalu holds a Zacks #3 Rank (short-term Hold rating).
Get the full Analyst Report on WMT - FREE
Get the full Analyst Report on SVU - FREE
Get the full Analyst Report on KR - FREE
Get the full Analyst Report on SWY - FREE